Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
1,200 | 1,200 | 15,141,542 | 1,611 | Compositions and methods of using them for protecting skin, hair and nails against exposure to high energy visible light are described. The compositions can include one or more natural oils or extracts which are effective to absorb the high energy visible light at least to some degree. | 1. A method of protecting cellular damage of an animal cell from exposure to incident high energy light comprising a wavelength of about 380 nm to about 500 nm, the method comprising topically administering a composition to the animal cell comprising at least one natural oil or extract present in an effective amount to... | Compositions and methods of using them for protecting skin, hair and nails against exposure to high energy visible light are described. The compositions can include one or more natural oils or extracts which are effective to absorb the high energy visible light at least to some degree.1. A method of protecting cellular... | 1,600 |
1,201 | 1,201 | 15,673,167 | 1,649 | The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. ... | 1-14. (canceled) 15. A method of inhibiting the formation of membrane attack complex (MAC) in a subject diagnosed with a neurodegenerative disorder or physical injury of a nerve, comprising administering to the subject a therapeutically effective amount of an inhibitor of a mammalian complement system, wherein the inhi... | The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. ... | 1,600 |
1,202 | 1,202 | 16,047,929 | 1,643 | An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions. | 1.-14. (canceled) 15. A method of killing a cancer cell having C3d complement protein on the surface thereof in a subject, the method comprising administering to the subject (1) an anti-C3d antibody or antibody fragment comprising a heavy chain variable region comprising
SEQ ID NO: 1 as heavy chain complementary determ... | An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.1.-14. (canceled) 15. A method of killing a cancer cell having C3d complement protein on the surface thereof in a subject, the method comprising administering to the subject (1) an anti-C3d antib... | 1,600 |
1,203 | 1,203 | 16,000,717 | 1,618 | A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative. | 1. A molecular probe for use in the detection of myelin in a subject comprising the general formula:
wherein R1 and R2 are each independently a hydrophilic or lipophilic group; wherein X1 is a double or triple bond; each R4-R13 is independently selected from the group consisting of H, F, Cl, Br, I, a lower al... | A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative.1. A molecular probe for use in the detection of myelin in a subject comprising the general formula:
wherein R1 and R2 are each independently a hydrophilic or lipophilic group; wherein X1 is a double or triple bond; each R4... | 1,600 |
1,204 | 1,204 | 14,441,135 | 1,653 | Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months. | 1. A hydrogel comprising:
(a) a hydrophilic gelling agent that includes a nonionic cellulose ether; and (b) active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months. 2. The hydrogel of claim 1, wherein the proteolytic activit... | Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.1. A hydrogel comprising:
(a) a hydrophilic gelling agent t... | 1,600 |
1,205 | 1,205 | 14,769,754 | 1,653 | Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when ... | 1. A dissolvable, gel-forming film comprising:
(a) a water-soluble cellulose ether; (b) a hydrophilic rheological modifying agent; and (c) a proteolytic enzyme, wherein the dissolvable, gel-forming film has a water content of less than 15% w/w, and the dissolvable, gel-forming film is capable of forming a hydrogel when... | Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when ... | 1,600 |
1,206 | 1,206 | 14,443,359 | 1,657 | Methods are disclosed for treating post traumatic stress disorder (PTSD) in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the s... | 1. A method for treating post traumatic stress disorder (PTSD) in a subject, comprising administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle, thereby treating the PTSD ... | Methods are disclosed for treating post traumatic stress disorder (PTSD) in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the s... | 1,600 |
1,207 | 1,207 | 15,335,547 | 1,617 | Disclosed are compositions and methods for the treatment of a subject having an autism spectrum disorder. The disclosed compositions may contain racemic ketamine or S-ketamine. The disclosed methods of administering the compositions include intranasal administration to a subject having an autism spectrum disorder. | 1.-15. (canceled) 16. An intranasal delivery device comprising a composition comprising racemic ketamine, wherein said delivery device is capable of administering a unit dose of from about 20 to about 120 mg. 17. The device according to claim 16, wherein said composition is substantially free of R-ketamine. 18. The dev... | Disclosed are compositions and methods for the treatment of a subject having an autism spectrum disorder. The disclosed compositions may contain racemic ketamine or S-ketamine. The disclosed methods of administering the compositions include intranasal administration to a subject having an autism spectrum disorder.1.-15... | 1,600 |
1,208 | 1,208 | 15,694,567 | 1,648 | Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephrop... | 1. A multivalent BK polyomavirus (BKV) immunogenic composition comprising:
a virus-like particle comprising at least one BKV serotype IV capsid polypeptide; a virus-like particle comprising at least one BKV serotype I capsid polypeptide; a pharmaceutically acceptable carrier; and an adjuvant. 2. The composition of clai... | Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephrop... | 1,600 |
1,209 | 1,209 | 15,308,085 | 1,633 | It is an object of the present invention to provide a chicken B cell that expresses a variety of human antibodies. The solution to the problem in the present invention is a chicken B cell, in which, in an antibody light chain gene locus thereof, all or a part of a DNA sequence derived from a human antibody light chain ... | 1. A chicken B cell, in which in chicken antibody light chain gene locus is replaced by the DNA sequence derived from a human antibody light chain variable region and by the DNA sequence derived from a human antibody light chain constant region,
which in the chicken antibody heavy chain gene locus all or a part of the ... | It is an object of the present invention to provide a chicken B cell that expresses a variety of human antibodies. The solution to the problem in the present invention is a chicken B cell, in which, in an antibody light chain gene locus thereof, all or a part of a DNA sequence derived from a human antibody light chain ... | 1,600 |
1,210 | 1,210 | 16,062,422 | 1,612 | The present invention relates to a in the form of an emulsion, in particular a water-in-oil emulsion, in particular comprising a physiologically acceptable medium, in particular for coating keratin materials, more particularly for making up and/or caring for keratin materials, such as the skin, containing: —at least on... | 1. A composition, in the form of an emulsion, comprising a physiologically acceptable medium, comprising:
at least one aqueous phase in a content from 60% to 80% by weight relative to the total weight of the composition; at least one oily phase at a concentration of less than 30.0% by weight relative to the total weigh... | The present invention relates to a in the form of an emulsion, in particular a water-in-oil emulsion, in particular comprising a physiologically acceptable medium, in particular for coating keratin materials, more particularly for making up and/or caring for keratin materials, such as the skin, containing: —at least on... | 1,600 |
1,211 | 1,211 | 14,649,803 | 1,634 | The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample ... | 1. Method for making an in vitro prognosis of severity for a patient in septic shock, comprising the following steps:
(i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from said patient, (ii) ... | The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample ... | 1,600 |
1,212 | 1,212 | 16,010,412 | 1,658 | The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan. | 1-31. (canceled) 32. A pharmaceutical composition comprising:
(a) at least one matrix-forming agent that is levan to form an open matrix network; and (b) at least one pharmaceutically active ingredient,
wherein the composition is an orodispersible pharmaceutical dosage form. 33. The pharmaceutical composition accordin... | The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.1-31. (canceled) 32. A pharmaceutical composition comprising:
(a) at least one matrix-forming agent that is levan to form an ... | 1,600 |
1,213 | 1,213 | 14,577,028 | 1,613 | Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system st... | 1. A composition for the transdermal delivery of amphetamine in the form of a flexible finite system for topical application, comprising a polymer matrix comprising a polymer and amphetamine or a pharmaceutically acceptable salt or prodrug thereof, wherein the composition comprises polyurethane in an amount effective t... | Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system st... | 1,600 |
1,214 | 1,214 | 16,207,546 | 1,617 | Provided is a method for producing an antithrombotic coating material in which a high molecular weight polymer can be obtained by a solution polymerization using a radical polymerization initiator. The above-mentioned task is achieved by a method for producing an antithrombotic coating material, including steps of: pre... | 1. An antithrombotic coating material, comprising:
polyalkoxyalkyl (meth)acrylate that contains a structural unit (A) represented by formula (2):
wherein in formula (2), R1 represents a hydrogen atom or a methyl group, R2 represents an alkylene group having 1 to 4 carbon atoms, and R3 represents an alkyl gr... | Provided is a method for producing an antithrombotic coating material in which a high molecular weight polymer can be obtained by a solution polymerization using a radical polymerization initiator. The above-mentioned task is achieved by a method for producing an antithrombotic coating material, including steps of: pre... | 1,600 |
1,215 | 1,215 | 16,278,025 | 1,656 | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1-22. (canceled) 23. A method for producing a biosensor for measuring glucose in a sample liquid comprising:
(i) obtaining a soluble flavin compound-binding glucose dehydrogenase secreted from an Aspergillus fungal body, which has enzymatic activity to glucose comprising catalyzing a reaction for oxidizing glucose in t... | The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method f... | 1,600 |
1,216 | 1,216 | 14,395,396 | 1,616 | Provided herein relates to silk fibroin-based compositions comprising non-hydrolyzed silk fibroin and a humectant agent and methods of making the same. In some embodiments, the silk fibroin-based compositions can be formulated for personal care products, e.g., but not limited to, cosmetic products, skin care products, ... | 1. A silk fibroin-based composition comprising non-hydrolyzed silk fibroin and a humectant agent. 2. The silk fibroin-based composition of claim 1, wherein the non-hydrolyzed silk fibroin has an average molecular weight of at least about 20 kDa or higher. 3. The silk fibroin-based composition of any of claims 1-3, wher... | Provided herein relates to silk fibroin-based compositions comprising non-hydrolyzed silk fibroin and a humectant agent and methods of making the same. In some embodiments, the silk fibroin-based compositions can be formulated for personal care products, e.g., but not limited to, cosmetic products, skin care products, ... | 1,600 |
1,217 | 1,217 | 14,394,051 | 1,644 | The present invention provides a composition for treating and/or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.), as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor, 2.) a mixture of a type I diabetes protein antige... | 1-11. (canceled) 12. A composition capable of eliciting a suppressive immune response against type 1 diabetes (TID), comprising an antigen and immunosuppressive agent. 13. The composition of claim 12, wherein the antigen is a protein antigen. 14. The composition of claim 12, wherein the antigen is a peptide antigen. 15... | The present invention provides a composition for treating and/or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.), as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor, 2.) a mixture of a type I diabetes protein antige... | 1,600 |
1,218 | 1,218 | 15,573,214 | 1,632 | The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptid... | 1. An adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence. 2. The AAV vector of claim 1, wherein the heterologous nucleic acid sequence is operably linked to regulatory s... | The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptid... | 1,600 |
1,219 | 1,219 | 15,569,073 | 1,612 | Disclosed are high-porosity protein particles useful for carrying one or more agents of interest, methods for their manufacture and use, and products comprising them. | 1. A method for preparing a porous protein particle, comprising:
providing a protein isolate; forming a protein isolate emulsion with an oil; drying the protein isolate emulsion to produce a powder; and extracting the oil from the powder to produce the porous protein particle. 2. The method of claim 1, wherein the prot... | Disclosed are high-porosity protein particles useful for carrying one or more agents of interest, methods for their manufacture and use, and products comprising them.1. A method for preparing a porous protein particle, comprising:
providing a protein isolate; forming a protein isolate emulsion with an oil; drying the p... | 1,600 |
1,220 | 1,220 | 14,815,251 | 1,631 | Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including patches and corresponding modules for wirelessly monitoring physiologic and/or physical signals is disclosed. A service system for managing the collection of physiologic da... | 1. A patch interface, comprising:
a substrate with a surface; an adhesive coupled to the substrate formulated for attachment to the skin of a subject; an interconnect embedded into or coupled to the substrate for attachment of the patch to a microcircuit; and a plurality microelectrodes attached to or embedded into the... | Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including patches and corresponding modules for wirelessly monitoring physiologic and/or physical signals is disclosed. A service system for managing the collection of physiologic da... | 1,600 |
1,221 | 1,221 | 15,321,770 | 1,622 | In an oxychlorination process of the type where ethylene is converted to 1,2-dichloroethane in the presence of a supported copper catalyst, the improvement comprising: the use of a supported catalyst prepared by (i) impregnating, within a first step, an alumina support with a first aqueous solution including copper, to... | 1. In an oxychlorination process of the type where ethylene is converted to 1,2-dichloroethane in the presence of a supported copper catalyst, the improvement comprising: the use of a supported catalyst prepared by (i) impregnating, within a first step, an alumina support with a first aqueous solution including copper ... | In an oxychlorination process of the type where ethylene is converted to 1,2-dichloroethane in the presence of a supported copper catalyst, the improvement comprising: the use of a supported catalyst prepared by (i) impregnating, within a first step, an alumina support with a first aqueous solution including copper, to... | 1,600 |
1,222 | 1,222 | 15,559,237 | 1,651 | Provided is a cell culture support using a water-soluble polymer, which is a support to which cells are attached to culture the cells, and which includes: a fibrous web having a plurality of pores in which fibers containing a water-soluble polymer and a synthetic polymer obtained by electrospinning are accumulated, and... | 1. A cell culture support using a water-soluble polymer, the cell culture support, which is a support to which cells are attached to culture the cells, the cell culture support comprising:
a fibrous web having a plurality of pores in which fibers containing a water-soluble polymer and a synthetic polymer obtained by el... | Provided is a cell culture support using a water-soluble polymer, which is a support to which cells are attached to culture the cells, and which includes: a fibrous web having a plurality of pores in which fibers containing a water-soluble polymer and a synthetic polymer obtained by electrospinning are accumulated, and... | 1,600 |
1,223 | 1,223 | 15,890,610 | 1,617 | Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, butylene glycol and water and the weight rat... | 1-32. (canceled) 33. A topical mometasone pharmaceutical composition in the form of an oil-in-water emulsion, comprising:
0.05%-0.2% w/w mometasone or a pharmaceutically acceptable ester thereof, calculated as mometasone furoate; 15-45% w/w of butylene glycol; 3-30% w/w vegetable oil; 1-15% w/w of one or more emulsifyi... | Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, butylene glycol and water and the weight rat... | 1,600 |
1,224 | 1,224 | 15,696,282 | 1,612 | An anhydrous stick composition, including deodorant active, an antiperspirant active, or a combination thereof; a carrier; a structurant; and a cyclodextrin perfume complex, comprising cyclodextrin and a perfume, wherein the perfume comprises perfume raw materials and 10% or more, by weight of the perfume, of the perfu... | 1. An anhydrous stick composition, comprising:
a) a deodorant active, an antiperspirant active, or a combination thereof; b) a carrier; c) a structurant; and d) a cyclodextrin perfume complex, comprising cyclodextrin and a perfume, wherein the perfume comprises perfume raw materials and 10% or more, by weight of the pe... | An anhydrous stick composition, including deodorant active, an antiperspirant active, or a combination thereof; a carrier; a structurant; and a cyclodextrin perfume complex, comprising cyclodextrin and a perfume, wherein the perfume comprises perfume raw materials and 10% or more, by weight of the perfume, of the perfu... | 1,600 |
1,225 | 1,225 | 15,671,217 | 1,646 | Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 1. An antibody produced by a method comprising the steps of:
i. expressing proGDF-8 (SEQ ID NO: 5); ii. forming a growth factor prodomain complex (GPC) by subjecting the expressed proGDF-8 (SEQ ID NO: 5) to enzymatic cleavage with one or more of furin, bone morphogenetic protein-1 (BMP-1), mammalian tolloid protein (mT... | Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins.1. An antibody produced by a method comprising the steps of:
i. expressing proGDF-8 (SEQ ID NO: 5); ii. for... | 1,600 |
1,226 | 1,226 | 16,318,209 | 1,618 | The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals. | 1. A radiolabeled compound having the following Formula I:
or a pharmaceutically acceptable salt thereof. 2. The radiolabeled compound of claim 1 having the following structure:
or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a diagnostically effective amo... | The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.1. A radiolabeled compound having the following Formula I:
or a pharmaceutically acceptable salt thereof. 2. The radiolabeled comp... | 1,600 |
1,227 | 1,227 | 15,299,085 | 1,641 | The invention discloses a method for reduction of autofluorescence in biological samples, comprising the steps of:
a) providing a biological microscopy sample; b) irradiating the sample with visible light, wherein the visible light has a spectrum such that at least 50% of the light intensity emanates from a ... | 1. A method for reduction of autofluorescence in biological samples, comprising the steps of:
a) providing one or more biological microscopy sample; b) irradiating said one or more sample with visible light having a light intensity, wherein a large fraction of said light intensity emanates from a narrow wavelength inte... | The invention discloses a method for reduction of autofluorescence in biological samples, comprising the steps of:
a) providing a biological microscopy sample; b) irradiating the sample with visible light, wherein the visible light has a spectrum such that at least 50% of the light intensity emanates from a ... | 1,600 |
1,228 | 1,228 | 15,799,919 | 1,619 | The invention relates to nail compositions including diisononyl 1,2-cyclohexanedicarboxylate, as well as to methods, kits and nail composition sets related to such compositions. | 1. A nail composition comprising at least 5% of diisononyl 1,2-cyclohexanedicarboxylate by weight with respect to the total weight of the composition. 2. The nail composition of claim 1, further comprising at least one cellulose compound, wherein the diisononyl 1,2-cyclohexanedicarboxylate and the cellulose compound ar... | The invention relates to nail compositions including diisononyl 1,2-cyclohexanedicarboxylate, as well as to methods, kits and nail composition sets related to such compositions.1. A nail composition comprising at least 5% of diisononyl 1,2-cyclohexanedicarboxylate by weight with respect to the total weight of the compo... | 1,600 |
1,229 | 1,229 | 15,167,822 | 1,644 | The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 1.-67. (canceled) 68. A nucleic acid encoding a polypeptide comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising an amino acid substitution at position 332 in the Fc region, wherein numbering is according to the EU index. 69. The nucleic acid according to claim 68, wherein the substitution at... | The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.1.-67. (canceled) 68. A nucleic acid encoding a polypeptide comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising an amino acid substitution at p... | 1,600 |
1,230 | 1,230 | 14,618,772 | 1,618 | An automated HPLC-based quality control system to perform quality control testing on a radiopharmaceutical solution shortly after synthesis. An automated HPLC-based quality control system makes efficient use of sample volume and is compatible with a variety of radioisotopes and radiopharmaceutical compounds. In several... | 1. A method for conducting quality control tests on a radiopharmaceutical using an automated quality control system comprising:
conveying a first portion of a radiopharmaceutical solution to a radiopharmaceutical solution pumping mechanism; conveying a second portion of said radiopharmetutical solution to a series of c... | An automated HPLC-based quality control system to perform quality control testing on a radiopharmaceutical solution shortly after synthesis. An automated HPLC-based quality control system makes efficient use of sample volume and is compatible with a variety of radioisotopes and radiopharmaceutical compounds. In several... | 1,600 |
1,231 | 1,231 | 15,300,686 | 1,633 | The present invention relates to a novel gene expression system comprising: a) a first nucleotide sequence encoding a fusion polypeptide of: a1) a destabilizing domain (DD) based on DHFR, and a2) a GTPcyclohydrolase 1 (GCH1) polypeptide, or a biologically active fragment or variant thereof; and b) a second nucleotide s... | 1. A gene expression system comprising:
a first nucleotide sequence encoding a fusion polypeptide of:
a) a destabilizing domain (DD), and
b) a GTPcyclohydrolase 1 (GCH1) polypeptide, or a biologically active fragment or variant thereof; and
a second nucleotide sequence encoding a tyrosine hydroxylase (TH) polypeptide,... | The present invention relates to a novel gene expression system comprising: a) a first nucleotide sequence encoding a fusion polypeptide of: a1) a destabilizing domain (DD) based on DHFR, and a2) a GTPcyclohydrolase 1 (GCH1) polypeptide, or a biologically active fragment or variant thereof; and b) a second nucleotide s... | 1,600 |
1,232 | 1,232 | 15,266,570 | 1,617 | The present invention provides antimicrobial feed supplement compositions comprising clay, and methods of treating microbial infections in an animal using the antimicrobial compositions. | 1. A method for controlling microbes, the method comprising contacting the microbes with an antimicrobial effective amount of an antimicrobial clay, wherein the clay is mined clay. 2. The method of claim 1, wherein the antimicrobial clay is clay mined in the Crater Lake region of the Cascade Mountains of Oregon. 3. The... | The present invention provides antimicrobial feed supplement compositions comprising clay, and methods of treating microbial infections in an animal using the antimicrobial compositions.1. A method for controlling microbes, the method comprising contacting the microbes with an antimicrobial effective amount of an antim... | 1,600 |
1,233 | 1,233 | 14,187,997 | 1,618 | Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ra... | 1-29. (canceled) 30. An oil-in-water emulsion comprising mometasone or a pharmaceutically acceptable derivative thereof and propylene glycol, wherein the concentration of propylene glycol is from about 20 to about 45% w/w. 31. The oil-in-water emulsion according to claim 30, wherein the concentration of propylene glyco... | Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ra... | 1,600 |
1,234 | 1,234 | 16,086,960 | 1,613 | A cosmetic composition capable of forming a multilayer structure after application to a keratinous material, wherein the cosmetic composition comprises at least two immiscible components A and B, wherein the component A comprises at least one silicone and/or hydrocarbon-containing film-forming agent and wherein the com... | 1: A cosmetic composition capable of forming a multilayer structure after application to a keratinous material, wherein the cosmetic composition comprises at least two immiscible components prior to application and wherein the at least two immiscible components are Component A and Component B. 2: A cosmetic composition... | A cosmetic composition capable of forming a multilayer structure after application to a keratinous material, wherein the cosmetic composition comprises at least two immiscible components A and B, wherein the component A comprises at least one silicone and/or hydrocarbon-containing film-forming agent and wherein the com... | 1,600 |
1,235 | 1,235 | 16,196,500 | 1,615 | The present invention includes a pharmaceutical composition, and methods of making and using, a pharmaceutical composition comprising one or more thyroid hormone(s) or analogs thereof, wherein a first portion of thyroid hormone(s) is formulated for immediate release and a second portion of thyroid hormone(s) is formula... | 1. A mixed-release pharmaceutical composition effective to treat hypothyroidism comprising: (i) a first portion comprising one or more thyroid hormones is formulated for immediate release, and (ii) a second portion comprising one or more thyroid hormones is formulated for modified release that is greater than 10% by we... | The present invention includes a pharmaceutical composition, and methods of making and using, a pharmaceutical composition comprising one or more thyroid hormone(s) or analogs thereof, wherein a first portion of thyroid hormone(s) is formulated for immediate release and a second portion of thyroid hormone(s) is formula... | 1,600 |
1,236 | 1,236 | 14,917,098 | 1,623 | The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need o... | 1. A method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising:
administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the in... | The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need o... | 1,600 |
1,237 | 1,237 | 15,316,188 | 1,642 | The present invention relates to extracellular microvesicles biomarkers for determining the tumour transformation status or presence of a tumour in a subject, and to the uses of such biomarkers and to diagnostics methods using such biomarkers. In particular, the methods and uses of the invention involve isolation of TM... | 1. A method for determining in vitro the presence of a tumour in a subject, such method comprising
a) providing a biological sample obtained from that subject, b) isolating extracellular vesicles from said sample, wherein this step of isolating extracellular vesicles comprises isolating TM9SF4-positive extracellular ve... | The present invention relates to extracellular microvesicles biomarkers for determining the tumour transformation status or presence of a tumour in a subject, and to the uses of such biomarkers and to diagnostics methods using such biomarkers. In particular, the methods and uses of the invention involve isolation of TM... | 1,600 |
1,238 | 1,238 | 15,334,600 | 1,654 | An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoul... | 1-3. (canceled) 4. A method for long-lasting enhancement of NO production comprising, administering an agent comprising citrulline or a salt thereof and glutathione or a salt thereof to a subject in need thereof. 5. The method for long-lasting enhancement of NO production according to claim 4, wherein the enhancement o... | An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoul... | 1,600 |
1,239 | 1,239 | 15,759,587 | 1,632 | A biological cell and/or tissue growth apparatus operable to create, in a chamber of the apparatus, a three-dimensional (3D) cell culture and to interact with a 3D structure of the cells in the chamber to, for example, apply materials to and/or remove materials from the cells or the chamber. The apparatus may include e... | 1. An apparatus for culturing and interacting with biological cells and/or tissues, the apparatus comprising:
a chamber comprising a container holding a three-dimensional (3D) cell growth medium, the 3D cell growth medium being a thixotropic material; equipment to dispense biological cells and/or tissues at particular ... | A biological cell and/or tissue growth apparatus operable to create, in a chamber of the apparatus, a three-dimensional (3D) cell culture and to interact with a 3D structure of the cells in the chamber to, for example, apply materials to and/or remove materials from the cells or the chamber. The apparatus may include e... | 1,600 |
1,240 | 1,240 | 14,892,702 | 1,662 | Methods are provided for hybrid seed production using 3-phyletic crosses between female, maintainer and male, particularly restorer lines, wherein the trait is introduced in the female line only at the stage of basic seed production via crossing of the female line with a maintainer line containing the gene or genes enc... | 1) A method for producing herbicide-tolerant hybrid seed using
a) a male-sterile plant line or A-line; b) a male-sterile plant line comprising a herbicide tolerance gene in heterozygous or hemizygous state or AHT-line; c) an isogenic maintainer plant line or B-line; d) an isogenic maintainer plant line comprising a her... | Methods are provided for hybrid seed production using 3-phyletic crosses between female, maintainer and male, particularly restorer lines, wherein the trait is introduced in the female line only at the stage of basic seed production via crossing of the female line with a maintainer line containing the gene or genes enc... | 1,600 |
1,241 | 1,241 | 15,502,924 | 1,631 | The present disclosure describes systems and methods for determining sources of infection transmission. Phylogenetic methods are used for determining the evolutionary history and replication rates of infection isolates. The evolutionary distance and/or replication rate of an infection isolate maybe compared to other is... | 1. A method, comprising:
receiving an electronic data representative of an infection isolate sequence; comparing the electronic data representative of the infection isolate sequence to at least one reference sequence stored in a database to determine variants between the infection isolate sequence and the at least one ... | The present disclosure describes systems and methods for determining sources of infection transmission. Phylogenetic methods are used for determining the evolutionary history and replication rates of infection isolates. The evolutionary distance and/or replication rate of an infection isolate maybe compared to other is... | 1,600 |
1,242 | 1,242 | 11,616,658 | 1,618 | Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and ... | 1. A delivery composition comprising:
an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and glucocerebroside(s); and a ... | Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and ... | 1,600 |
1,243 | 1,243 | 15,632,233 | 1,615 | The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a microcrystalline structure and techniques for increasing vascular permeability for drug application and retention. Particular aspects may be directed to a medical device including a balloon having an outer... | 1. A medical device comprising:
a balloon comprising an outer surface; and a drug coating layer on the outer surface of the balloon, wherein the drug coating layer comprises microcrystals in a haystack orientation having random and a substantial absence of uniformity in placement on the outer surface of the balloon. 2.... | The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a microcrystalline structure and techniques for increasing vascular permeability for drug application and retention. Particular aspects may be directed to a medical device including a balloon having an outer... | 1,600 |
1,244 | 1,244 | 14,549,467 | 1,636 | Provided are detection means and method specific for the genus Cronobacter ( E. sakazakii ) which are sensitive by using a target molecule which is multiple existent in Cronobacter cells. | 1-15. (canceled) 16. A kit for the detection of the genus Cronobacter comprising
a nucleic acid comprising SEQ ID NO:2 or a variant thereof, together with a nucleic acid comprising SEQ ID NO:3 or a variant thereof, wherein the variant is
a) a sequence which is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:3, respe... | Provided are detection means and method specific for the genus Cronobacter ( E. sakazakii ) which are sensitive by using a target molecule which is multiple existent in Cronobacter cells.1-15. (canceled) 16. A kit for the detection of the genus Cronobacter comprising
a nucleic acid comprising SEQ ID NO:2 or a varia... | 1,600 |
1,245 | 1,245 | 14,773,038 | 1,619 | Disclosed herein is an aqueous hair care composition capable of providing durable non-permanent hair styling and/or wash-resistant retention of shape of hair fibers comprising a polyelectrolyte complex having a gel matrix structure or a mixture of gel matrix and microgel formed by electrostatic attraction, wherein the ... | 1. An aqueous hair care composition capable of providing durable non-permanent hair styling and/or wash-resistant retention of shape of hair fibers comprising a polyelectrolyte complex having a gel matrix structure or a mixture of gel matrix and microgel formed by electrostatic attraction, wherein the polyelectrolyte c... | Disclosed herein is an aqueous hair care composition capable of providing durable non-permanent hair styling and/or wash-resistant retention of shape of hair fibers comprising a polyelectrolyte complex having a gel matrix structure or a mixture of gel matrix and microgel formed by electrostatic attraction, wherein the ... | 1,600 |
1,246 | 1,246 | 15,778,693 | 1,613 | The present invention belongs to the area of cosmetics, especially to a delivery system for actives to the skin, such as face masks and facial masks. Particularly, the present invention refers to a delivery system consisting of a basic body comprises nonwoven fibrous materials and an active-substance preparation which ... | 1. A delivery system comprising
(i) a basic body, (ii) an active-substance preparation, and (iii) a separate wetting liquid,
wherein (i) the basic body comprises a non-woven fibrous material, (ii) the active-substance preparation is an o/w emulsion which is printed onto the basic body (i) and (iii) the wetting liquid ... | The present invention belongs to the area of cosmetics, especially to a delivery system for actives to the skin, such as face masks and facial masks. Particularly, the present invention refers to a delivery system consisting of a basic body comprises nonwoven fibrous materials and an active-substance preparation which ... | 1,600 |
1,247 | 1,247 | 16,072,088 | 1,625 | Disclosed herein, in part, are compounds and methods for their use in the treatment of malaria. In at least one specific embodiment, the compounds or salts thereof can include compounds of Formula (I): | 1. A compound or a salt thereof, the compound comprising a Formula (I):
wherein R1 is selected from H, F, Cl, Br, I, CN, CH3, CF3, alkyl, halogenated alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, aryloxy, arylalkoxy, heteroalkyl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, hydro... | Disclosed herein, in part, are compounds and methods for their use in the treatment of malaria. In at least one specific embodiment, the compounds or salts thereof can include compounds of Formula (I):1. A compound or a salt thereof, the compound comprising a Formula (I):
wherein R1 is selected from H, F, Cl,... | 1,600 |
1,248 | 1,248 | 12,689,370 | 1,634 | A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucl... | 1. A non-invasive prenatal screening method for the identification of fetal characteristics, comprising the steps of:
a. contacting a drawn maternal blood sample that includes a plurality of blood cells with a nucleic acid protective agent in an amount and time sufficient so that the blood cells are substantially preve... | A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucl... | 1,600 |
1,249 | 1,249 | 15,993,172 | 1,649 | Provided herein are methods and compositions for treating inflammatory diseases by administering to the subject an effective dose on an anti-α 5 agent. | 1. A method for treating an inflammatory disease or condition in a patient, the method comprising:
administering to said patient a therapeutically effective dose of an anti-integrin-α5 agent. 2. The method of claim 1, wherein the patient is a human. 3. The method of claim 1, wherein the inflammatory disease is multiple... | Provided herein are methods and compositions for treating inflammatory diseases by administering to the subject an effective dose on an anti-α 5 agent.1. A method for treating an inflammatory disease or condition in a patient, the method comprising:
administering to said patient a therapeutically effective dose of an ... | 1,600 |
1,250 | 1,250 | 15,117,896 | 1,628 | The present invention discloses the use of paricalcitol, a synthetic Vitamin D analogue, in the treatment of inflammatory anaemia, preferably in combination with erythropoeisis-stimulating agents. The use of paricalcitol in the treatment of said pathology is associated with a reduced requirement for erythropoeisis-stim... | 1. A method of treating inflammatory anaemia, said method comprising administering paricalcitol to a subject in need thereof, wherein the dose of paricalcitol to be administered is between 5-10 μg/week. 2. The method of claim 1, wherein the dose of paricalcitol to be administered is 1 μg/day. 3. The method of claim 1, ... | The present invention discloses the use of paricalcitol, a synthetic Vitamin D analogue, in the treatment of inflammatory anaemia, preferably in combination with erythropoeisis-stimulating agents. The use of paricalcitol in the treatment of said pathology is associated with a reduced requirement for erythropoeisis-stim... | 1,600 |
1,251 | 1,251 | 14,426,485 | 1,623 | The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug. | 1. A hyaluronic acid derivative comprising a repeating unit represented by formula (I):
[where R1, R2, R3, and R4 are independently selected from a hydrogen atom, C1-6 alkyl, formyl, and C1-6 alkylcarbonyl;
R5 is a hydrogen atom, formyl, or C1-6 alkylcarbonyl;
X1 is hydroxy, —O-Q+, C1-6 alkoxy, —NR7R8, or —NR... | The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.1. A hyaluronic acid derivative comprising a repeating unit represented by formula (I):
[where R1, R... | 1,600 |
1,252 | 1,252 | 16,308,050 | 1,612 | Sunscreen composition including a combination of a linear ultraviolet radiation absorbing polyether that includes a covalently bound UV-chromophore, and at least one non-polymeric UV-screening compounds. | 1. A sunscreen composition, comprising:
a polymer composition comprising a linear, ultraviolet radiation absorbing polyether comprising a covalently bound UV-chromophore; and at least one additional UV screening compound. 2. The composition of claim 1 wherein said additional UV-screening compound is avobenzone. 3. The ... | Sunscreen composition including a combination of a linear ultraviolet radiation absorbing polyether that includes a covalently bound UV-chromophore, and at least one non-polymeric UV-screening compounds.1. A sunscreen composition, comprising:
a polymer composition comprising a linear, ultraviolet radiation absorbing po... | 1,600 |
1,253 | 1,253 | 14,979,181 | 1,662 | This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran pests. The disclosure also concerns methods for making transgenic plants that e... | 1. An isolated nucleic acid comprising at least one polynucleotide operably linked to a heterologous promoter, wherein the polynucleotide is selected from the group consisting of:
SEQ ID NO:1; the complement of SEQ ID NO:1; a fragment of at least 15 contiguous nucleotides of SEQ ID NO:1; the complement of a fragment of... | This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran pests. The disclosure also concerns methods for making transgenic plants that e... | 1,600 |
1,254 | 1,254 | 15,892,078 | 1,623 | Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes. | 1. A method of treating a condition selected from the group consisting of pre-diabetes, metabolic syndrome, hyperglycemia, and diabetes in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of citrulline and a therapeutically effective amount of leucine or a... | Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.1. A method of treating a condition selected from the gro... | 1,600 |
1,255 | 1,255 | 13,885,588 | 1,618 | The present invention relates to a solid makeup and/or care cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: —one pulverulent phase, —one emulsifying system, —one hydrophilic gelling agent, and—one hydrophilic active agent present in a content of greate... | 1. A solid makeup composition, a care cosmetic composition, or any combination thereof, comprising, in a physiologically acceptable medium:
a pulverulent phase, an emulsifying system, a hydrophilic gelling agent, and a hydrophilic active agent in a content of greater than or equal to 10% by weight relative to a total w... | The present invention relates to a solid makeup and/or care cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: —one pulverulent phase, —one emulsifying system, —one hydrophilic gelling agent, and—one hydrophilic active agent present in a content of greate... | 1,600 |
1,256 | 1,256 | 15,529,680 | 1,612 | An oral care mouth rinse composition containing at least one source of ionic tin and at least one aliphatic di- or tri-carboxylic acid in free or salt form, wherein the at least one aliphatic di- or tri-carboxylic acid in free or salt form is present in an amount of from 0.05 to 0.30 weight % based on the total weight ... | 1. An oral care mouth rinse composition comprising
(i) at least one source of ionic tin and (ii) at least one aliphatic di- or tri-carboxylic acid in free or salt form wherein the at least one aliphatic di- or tri-carboxylic acid in free or salt form is present in an amount of from 0.05 to 0.30 weight % based on the to... | An oral care mouth rinse composition containing at least one source of ionic tin and at least one aliphatic di- or tri-carboxylic acid in free or salt form, wherein the at least one aliphatic di- or tri-carboxylic acid in free or salt form is present in an amount of from 0.05 to 0.30 weight % based on the total weight ... | 1,600 |
1,257 | 1,257 | 15,311,714 | 1,635 | Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same. | 1. An aptamer that binds C3 protein, wherein the aptamer comprises the sequence 5′-KPGRMPDVD.LPAWPSVGPAYRPP-3′ (SEQ ID NO: 152)
wherein,
K is a C-5 modified pyrimidine, C, U, T, G, or a 3-carbon spacer;
each P is independently, and for each occurrence, a C-5 modified pyrimidine;
each R is independently, and for each oc... | Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same.1. An aptamer that binds C3 protein, wherein the aptamer comprises the sequence 5′-KPGRMPDVD.LPAWPSVGPAYRPP-3′ (SEQ ID N... | 1,600 |
1,258 | 1,258 | 15,401,777 | 1,627 | The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific pr... | 1. A combination comprising:
a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof and a second compound,
wherein M is selected from the group consisting of H and alkyl;
Z is selected from the group consisting of —CF3, —CF2H and —C2F5;
each of R1, R2, R3, and R4 is independently ... | The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific pr... | 1,600 |
1,259 | 1,259 | 14,600,564 | 1,649 | A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide incl... | 1. A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject, the method comprising:
administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation, the therapeuti... | A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide incl... | 1,600 |
1,260 | 1,260 | 15,000,504 | 1,613 | A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) Paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. chronic or acute pain, characterized in that comp... | 1. A composition comprising:
(a) at least one 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound corresponding to formula (I),
or a solvate or an acid addition salt thereof, and
(b) Paracetamol or a derivative thereof. 2. The composition of claim 1, wherein said compound corresponding to formula (I... | A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) Paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. chronic or acute pain, characterized in that comp... | 1,600 |
1,261 | 1,261 | 14,387,331 | 1,623 | The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture... | 1. A process for producing a low endotoxin alkali chitosan, the process comprising the steps of:
(a) contacting chitosan with an alkali solution to form a mixture; and (b) leaving the mixture for at least about 12 hours. 2. A process as claimed in claim 1, wherein the process further comprises a step (c) of drying the ... | The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture... | 1,600 |
1,262 | 1,262 | 13,814,963 | 1,613 | The present disclosure relates to silicone based cosmetic compositions comprising at least at least one silicone amine, at least one anionic silicone and a cosmetically acceptable carrier such as water and other components. The compositions are useful for treating keratinous substrates such as hair, for example, for st... | 1. A cosmetic composition comprising:
(a) at least one silicone amine; (b) at least one anionic silicone; and (c) a cosmetically acceptable carrier. 2. The cosmetic composition of claim 1, wherein the at least one silicone amine (a) is chosen from amodimethicone, trimethylsilylamodimethicone, aminopropyl phenyltrimethi... | The present disclosure relates to silicone based cosmetic compositions comprising at least at least one silicone amine, at least one anionic silicone and a cosmetically acceptable carrier such as water and other components. The compositions are useful for treating keratinous substrates such as hair, for example, for st... | 1,600 |
1,263 | 1,263 | 15,277,877 | 1,618 | Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are... | 1-35. (canceled) 36. A composition comprising a poly(amidoamine) (PAMAM) dendrimer covalently conjugated via a terminal functional group to an amino acid linker,
wherein the amino acid linker after conjugation to the dendrimer comprises at least two different chemical reactive groups. 37. The composition of claim 36, w... | Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are... | 1,600 |
1,264 | 1,264 | 14,973,765 | 1,615 | The present invention relates to an anhydrous cosmetic composition for topical application to skin in the intimate area. The compositions can be used following shaving or trimming hair in the intimate area. The compositions can also be used in the intimate skin area for consumers that wear absorbent articles against th... | 1. An anhydrous cosmetic composition for topical application comprising:
one or more complexed or encapsulated compounds having a thiol vapor pressure suppression index (TVPS) of more than 20 when measured according to the test methodology described herein, wherein the anhydrous cosmetic composition is in the form of a... | The present invention relates to an anhydrous cosmetic composition for topical application to skin in the intimate area. The compositions can be used following shaving or trimming hair in the intimate area. The compositions can also be used in the intimate skin area for consumers that wear absorbent articles against th... | 1,600 |
1,265 | 1,265 | 14,409,066 | 1,616 | One subject of the present invention is a translucent cosmetic composition in the form of an oil-in-water emulsion comprising: (1) a dispersed fatty phase comprising at least one oil; (2) a continuous aqueous phase comprising at least one hydrophilic thickening polymer; and (3) hydrophobic silica aerogel particles; the... | 1. A translucent cosmetic composition in the form of an oil-in-water emulsion comprising:
(1) a dispersed fatty phase comprising at least one oil; (2) a continuous aqueous phase comprising at least one hydrophilic thickening polymer; and (3) hydrophobic silica aerogel particles; the ratio of the amount by weight of sil... | One subject of the present invention is a translucent cosmetic composition in the form of an oil-in-water emulsion comprising: (1) a dispersed fatty phase comprising at least one oil; (2) a continuous aqueous phase comprising at least one hydrophilic thickening polymer; and (3) hydrophobic silica aerogel particles; the... | 1,600 |
1,266 | 1,266 | 15,571,575 | 1,628 | The present invention relates to methods for controlling and/or preventing infestation of stinkbugs, comprising applying to a crop of plants, the locus thereof, or propagation material thereof, a compound of formula I wherein R 1 , R 6a , R 6b Q, W, A 1 , A 2 , A 3 , A 4 , Z 1 , Z 2 and Z 3 are as defined in the desc... | 1. A method of controlling and/or preventing infestation of stinkbugs comprising applying to a crop of plants, the locus thereof, or propagation material thereof, a compound of formula (I)
wherein
R1 is selected from H, C1-C6-alkyl, C3-C6 alkenyl, C3-C6 alkinyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3-alkyl... | The present invention relates to methods for controlling and/or preventing infestation of stinkbugs, comprising applying to a crop of plants, the locus thereof, or propagation material thereof, a compound of formula I wherein R 1 , R 6a , R 6b Q, W, A 1 , A 2 , A 3 , A 4 , Z 1 , Z 2 and Z 3 are as defined in the desc... | 1,600 |
1,267 | 1,267 | 15,245,855 | 1,627 | A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form compri... | 1. A composition comprising:
(a) at least one 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound corresponding to formula (I),
or a solvate or an acid addition salt thereof, and
(b) one or more non-steroidal anti-inflammatory drugs (NSAIDs). 2. The composition of claim 1, wherein said compound corr... | A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form compri... | 1,600 |
1,268 | 1,268 | 13,520,689 | 1,619 | A constitution in which at least 5 to 30% by mass of titanium oxide, an acid dye or an organic pigment, an alkali-soluble type acryl resin and water are contained is employed in order to provide aqueous cosmetics having the respective compositions in an acid dye aqueous cosmetic containing titanium oxide and an acid dy... | 1. An aqueous cosmetic containing at least 5 to 30% by mass of titanium oxide, an acid dye, an alkali-soluble type acryl resin and water. 2. An aqueous cosmetic containing at least 5 to 30% by mass of titanium oxide, an organic pigment, an alkali-soluble type acryl resin and water. 3. The aqueous cosmetic as described ... | A constitution in which at least 5 to 30% by mass of titanium oxide, an acid dye or an organic pigment, an alkali-soluble type acryl resin and water are contained is employed in order to provide aqueous cosmetics having the respective compositions in an acid dye aqueous cosmetic containing titanium oxide and an acid dy... | 1,600 |
1,269 | 1,269 | 15,581,993 | 1,613 | The instant disclosure relates to essentially anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more bis-urea derivatives; and one or more solvents. Additional components such as silicones, auxiliary agents, etc., can also... | 1. An essentially anhydrous hair-treatment composition comprising:
one or more polyurethane latex polymers; one or more bis-urea derivatives of formula (I):
wherein R is a C3-C18 linear, branched, or cyclic moiety; and
R′ and R″ may be the same or different and are selected from the group consisting of C1-C... | The instant disclosure relates to essentially anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more bis-urea derivatives; and one or more solvents. Additional components such as silicones, auxiliary agents, etc., can also... | 1,600 |
1,270 | 1,270 | 15,569,320 | 1,617 | The present invention relates to a multi-step process for the production of nitrogen monoxide (NO) from a pH-labile NO donor in the presence of at least one antioxidant. The invention also relates to a device for implementation of said process and the use of said device for the treatment of diseases. Moreover, the inve... | 1. A process for the production of nitrogen monoxide (NO), comprising:
(a) providing a carrier medium comprising at least one pH-labile NO donor; (b) adjusting a pH value of the carrier medium to a pH value that induces degradation of the at least one pH-labile NO donor while producing NO; (c) maintaining the pH value ... | The present invention relates to a multi-step process for the production of nitrogen monoxide (NO) from a pH-labile NO donor in the presence of at least one antioxidant. The invention also relates to a device for implementation of said process and the use of said device for the treatment of diseases. Moreover, the inve... | 1,600 |
1,271 | 1,271 | 15,039,134 | 1,617 | A composition for wound healing and/or skin treatment comprises honey and a carbonate and/or bicarbonate salt. The salt is preferably capable of releasing CO 2 . The composition may optionally comprise thickeners and/or organic acids. Wound dressings, kits and treatment methods are also provided. | 1. A topical desloughing, debriding, wound treating, exfoliating or cosmetic composition comprising:
honey and/or a honey substitute; and, a pharmaceutically acceptable carbonate (CO3 −2) and/or bicarbonate (HCO3 −1) salt. 2. The composition according to claim 1, wherein said honey is produced by bees that have fed exc... | A composition for wound healing and/or skin treatment comprises honey and a carbonate and/or bicarbonate salt. The salt is preferably capable of releasing CO 2 . The composition may optionally comprise thickeners and/or organic acids. Wound dressings, kits and treatment methods are also provided.1. A topical desloughin... | 1,600 |
1,272 | 1,272 | 14,317,392 | 1,616 | Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of... | 1. A method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period wherein the physical barrier does not cause black spot defect in dairy products made with milk from the animal, the method comprising:
infusing an amount of a ... | Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of... | 1,600 |
1,273 | 1,273 | 14,916,439 | 1,619 | This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodid... | 1. A method for the preparation of a composition comprising microparticles or nanoparticles having negative surface charges, said method comprising producing said microparticles or nanoparticles with a pharmaceutically acceptable polymer using either an emulsion process or a precipitation process:
(a) wherein said emul... | This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodid... | 1,600 |
1,274 | 1,274 | 15,850,364 | 1,647 | Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the ... | 1-10. (canceled) 11. A biodegradable polymeric vascular graft or conduit comprising monocyte chemoattractant protein 1 (MCP-1), wherein the MCP-1 is locally released from the graft in an effective amount following graft implantation to recruit an effective amount of host monocytes to the graft within one week of graft ... | Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the ... | 1,600 |
1,275 | 1,275 | 14,912,657 | 1,617 | A method of providing anesthesia and organ-protection to a subject in need thereof comprises co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent in an amount effective to provide anesthesia, at normobaric conditions. | 1. A method of providing anesthesia and organ-protection to a subject in need thereof, comprising co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent in an amount effective to provide anesthesia, at normobaric conditions. 2. The ... | A method of providing anesthesia and organ-protection to a subject in need thereof comprises co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent in an amount effective to provide anesthesia, at normobaric conditions.1. A method o... | 1,600 |
1,276 | 1,276 | 16,576,485 | 1,617 | The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises:
(a) a therapeutically effective amount of a medicament; (b) 0.5 to 50% by weight of a water-soluble polymer; and (c) 1 to 25% by weight of a water-insoluble polymer applied as an aqueous ... | 1. A unit dosage form, in the form of an oral capsule comprising a plurality of pellets, said pellets comprising:
(a) a therapeutically effective amount of carbamazepine; (b) a sustained release water-soluble polymer; and (c) a water-insoluble polymer that is substantially water-insoluble in aqueous medium independent ... | The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises:
(a) a therapeutically effective amount of a medicament; (b) 0.5 to 50% by weight of a water-soluble polymer; and (c) 1 to 25% by weight of a water-insoluble polymer applied as an aqueous ... | 1,600 |
1,277 | 1,277 | 15,752,936 | 1,658 | The present invention relates to lysobactin for use in the treatment of bovine mastitis. | 1. Lysobactin for use in the treatment of bovine mastitis. 2. Lysobactin for use in the treatment of bovine mastitis according to claim 1, wherein lysobactin is administered intramammarily. 3. Lysobactin for use in the treatment of bovine mastitis according to claim 1 or 2, wherein the bovine mastitis is a clinically m... | The present invention relates to lysobactin for use in the treatment of bovine mastitis.1. Lysobactin for use in the treatment of bovine mastitis. 2. Lysobactin for use in the treatment of bovine mastitis according to claim 1, wherein lysobactin is administered intramammarily. 3. Lysobactin for use in the treatment of ... | 1,600 |
1,278 | 1,278 | 15,750,318 | 1,628 | Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are ... | 1. A pharmaceutical composition comprising a MAPK inhibitor and a reagent that downregulates or reduces TFAM, TRAP-1, PPRC1, or ESSRA. 2-3. (canceled) 4. The composition according to claim 1, wherein the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dab... | Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are ... | 1,600 |
1,279 | 1,279 | 16,401,725 | 1,615 | A sunscreen composition includes a silicone phase that includes at least one silicone film former, a blend of silicones that includes at least one of each of a low viscosity silicone fluid, a silicone co-emulsifier and a self-emulsifying silicone elastomer. The composition includes a UV filter system that includes one ... | 1. A sunscreen composition, comprising:
a) a silicone phase that comprises:
1) at least one silicone film former present from about 0.1% to about 5.0% by weight, based on the total weight of the composition;
2) a blend of silicones present from about 20% to about 35% by weight, based on the total weight of the composit... | A sunscreen composition includes a silicone phase that includes at least one silicone film former, a blend of silicones that includes at least one of each of a low viscosity silicone fluid, a silicone co-emulsifier and a self-emulsifying silicone elastomer. The composition includes a UV filter system that includes one ... | 1,600 |
1,280 | 1,280 | 15,052,016 | 1,623 | The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture... | 1-17. (canceled) 18: A low endotoxin alkali chitosan produced by a process comprising the steps of:
(a) contacting chitosan with an alkali solution to form a mixture; and (b) leaving the mixture for at least about 12 hours. 19: An alkali chitosan, a neutral chitosan, a chitosan salt, or a chitosan derivative comprising... | The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture... | 1,600 |
1,281 | 1,281 | 14,893,627 | 1,617 | The present invention relates to a cosmetic composition in the form of an O/W emulsion, comprising, in a cosmetically acceptable medium: (a) at least one aqueous phase comprising water; (b) at least one fatty phase comprising, (i) at least one polar oil, (ii) at least one lipophilic UV filter, and (iii) at least one fa... | 1.-15. (canceled) 16. A cosmetic composition in the form of an O/W emulsion, comprising, in a cosmetically acceptable medium:
(a) at least one aqueous phase comprising water; (b) at least one fatty phase comprising,
(i) at least one polar oil,
(ii) at least one lipophilic UV filter, and
(iii) at least one fatty acid;
... | The present invention relates to a cosmetic composition in the form of an O/W emulsion, comprising, in a cosmetically acceptable medium: (a) at least one aqueous phase comprising water; (b) at least one fatty phase comprising, (i) at least one polar oil, (ii) at least one lipophilic UV filter, and (iii) at least one fa... | 1,600 |
1,282 | 1,282 | 16,236,899 | 1,618 | A new nanoparticle (NP)-based, multicomponent delivery/reporter construct can mediate the controlled, spatiotemporal, active release of an appended cargo to the cytosol of mammalian cells. The construct comprises components including (1) a central NP scaffold, for example a photoluminescent quantum dot (QD); (2) a brid... | 1. A nanoparticle construct comprising:
a nanoparticle configured as a central scaffold; a molecule configured as a bridging structure and comprising a first binding element configured for attachment to the nanoparticle and a second binding element; and a cargo incorporating a ligand configured to allow for releasable ... | A new nanoparticle (NP)-based, multicomponent delivery/reporter construct can mediate the controlled, spatiotemporal, active release of an appended cargo to the cytosol of mammalian cells. The construct comprises components including (1) a central NP scaffold, for example a photoluminescent quantum dot (QD); (2) a brid... | 1,600 |
1,283 | 1,283 | 16,263,464 | 1,612 | The present invention relates to a mousse composition including water, at least one C2-C5 alcohol, at least one salt, at least one amphiphilic polymer, and at least one hydrophobic surface-treated pigment, as well as to methods for making-up and enhancing the appearance of keratinous materials using the mousse composit... | 1. A mousse composition comprising water, at least one C2-C5 alcohol, at least one salt, at least one amphiphilic polymer, and at least one hydrophobic surface-treated pigment, wherein the mousse composition is free of propellants and wherein the at least one hydrophobic surface-treated pigment has a hydrophobic surfac... | The present invention relates to a mousse composition including water, at least one C2-C5 alcohol, at least one salt, at least one amphiphilic polymer, and at least one hydrophobic surface-treated pigment, as well as to methods for making-up and enhancing the appearance of keratinous materials using the mousse composit... | 1,600 |
1,284 | 1,284 | 13,784,578 | 1,653 | Methods for processing and sorting sperm are disclosed. Portions of sperm sorting or staining processes may include standardizing sperm samples by adjusting the concentration of the sperm sample to a predetermined concentration and adjusting the pH of the sample to a predetermined value. Sperm may also be stained in a ... | 1. A method of processing sperm comprising the steps of:
a) obtaining a sperm sample; b) adjusting the concentration of the sperm sample to a predetermined concentration; c) adjusting the pH of the sperm sample towards a predetermined pH; and d) staining the sperm sample with a DNA selective dye. 2. The method of claim... | Methods for processing and sorting sperm are disclosed. Portions of sperm sorting or staining processes may include standardizing sperm samples by adjusting the concentration of the sperm sample to a predetermined concentration and adjusting the pH of the sample to a predetermined value. Sperm may also be stained in a ... | 1,600 |
1,285 | 1,285 | 15,298,757 | 1,644 | A pharmaceutical product containing β2-microglobulin or a functional variant thereof as an active ingredient in the form of liposomes is provided. The product can increase the concentration of β2-microglobulin in the blood, and can also restore a normal HC/β2-microglobulin molar ratio within membrane MHC-I complexes, o... | 1. A method of treating an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical product comprising as an active ingredient β2-microglobulin or a functional variant thereof presenting at least 90% identity with the human 62-microglobulin protein, in a pharmace... | A pharmaceutical product containing β2-microglobulin or a functional variant thereof as an active ingredient in the form of liposomes is provided. The product can increase the concentration of β2-microglobulin in the blood, and can also restore a normal HC/β2-microglobulin molar ratio within membrane MHC-I complexes, o... | 1,600 |
1,286 | 1,286 | 14,730,396 | 1,649 | The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-de... | 1. A peptide for a use as a psychostimulant, wherein said peptide:
comprises a maturation product of the Basic Proline-rich Lacrimal Protein (BPLP) of sequence SEQ ID NO: 5 or a derivative of said maturation product; and exerts a psychostimulant activity. 2. A peptide for activating an opioidergic pathway depending on ... | The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-de... | 1,600 |
1,287 | 1,287 | 15,252,267 | 1,644 | Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis... | 1. A method for treating metastatic cancer in a patient having metastatic cancer or for preventing metastasis in a cancer patient at risk for metastasis comprising administering to the patient a monoclonal antibody, or a fragment thereof, that binds to B7x, in an amount effective to treat or prevent metastasis in a pat... | Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis... | 1,600 |
1,288 | 1,288 | 16,022,835 | 1,631 | The present disclosure provides, in some embodiments, a computing device comprising an improved user interface. In some embodiments, the improved user interface enables the visualization of clinically relevant information pertaining to interacting gene variants, including therapeutic recommendations. In some embodiment... | 1-12. (canceled) 13. A method for treating a human patient comprising:
receiving a user input of a diagnosed disease or condition of a human patient, wherein the diagnosed disease or condition is a type of cancer; based on the received user input, displaying, on a computing device having a display screen, a first repre... | The present disclosure provides, in some embodiments, a computing device comprising an improved user interface. In some embodiments, the improved user interface enables the visualization of clinically relevant information pertaining to interacting gene variants, including therapeutic recommendations. In some embodiment... | 1,600 |
1,289 | 1,289 | 15,953,287 | 1,633 | Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstu... | 1-20. (canceled) 21. A method of identifying a xenohormetic agent, said method comprising:
a) identifying a first organism as a xenohormetic organism; b) screening the proteome of said first organism for one or more candidate xenohormetic agents; c) contacting said one or more candidate xenohormetic agents with a test ... | Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstu... | 1,600 |
1,290 | 1,290 | 14,020,694 | 1,662 | An Engineered Transgene Integration Platform (ETIP) is described that can be inserted randomly or at targeted locations in plant genomes to facilitate rapid selection and detection of a GOI that is perfectly targeted (both the 3′ and 5′ ends) at the ETIP genomic location. One element in the invention is the introductio... | 1. A method for generating a plant from a population of plant cells comprising isolating a plant protoplast comprising a polynucleotide of interest, the method comprising:
providing a population of plant protoplasts having at least one protoplast comprising a polynucleotide of interest and a fluorescent marker, wherein... | An Engineered Transgene Integration Platform (ETIP) is described that can be inserted randomly or at targeted locations in plant genomes to facilitate rapid selection and detection of a GOI that is perfectly targeted (both the 3′ and 5′ ends) at the ETIP genomic location. One element in the invention is the introductio... | 1,600 |
1,291 | 1,291 | 15,514,651 | 1,699 | The use of neridronic acid or a salt thereof in the treatment of osteoarthritis is described. In particular, neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical and mobility disabilities, as well as subchondral bone marrow lesions... | 1. A method of treating osteoarthritis comprising administering a therapeutically effective amount of neridronic acid or a salt thereof to patients in need thereofs. 2. The method of claim 1, wherein the treatment of osteoarthritis comprises alleviating the pain symptomathology of joint pain. 3. The method of claim 1, ... | The use of neridronic acid or a salt thereof in the treatment of osteoarthritis is described. In particular, neridronic acid or a salt thereof has been shown to be able to reduce significantly the symptoms of osteoarthritis, such as pain and physical and mobility disabilities, as well as subchondral bone marrow lesions... | 1,600 |
1,292 | 1,292 | 15,652,679 | 1,616 | Compounds contained herein relate to polyalkoxylated polyol polyesters having a viscosity that allows a product to be poured, yet retained on a desired surface to which it is applied. Embodiments of the compounds may be exemplified by the formula:
Q-[(OA) n —OR] m | 1. A polyalkoxylated polyols polyester comprising the formula:
Q-[(OA)n—OR]m Formula-2
Q is a radical of natural or synthetic organic polyol compounds having from 6 to 50 carbon atoms forming a straight, a branched, a cyclic, a saturated, or an unsaturated structure, with each carbon atom being independently substi... | Compounds contained herein relate to polyalkoxylated polyol polyesters having a viscosity that allows a product to be poured, yet retained on a desired surface to which it is applied. Embodiments of the compounds may be exemplified by the formula:
Q-[(OA) n —OR] m1. A polyalkoxylated polyols polyester comprisin... | 1,600 |
1,293 | 1,293 | 15,652,602 | 1,616 | Compounds contained herein relate to polyalkoxylated polyol polyester having a viscosity that allows a product to be poured, yet retained on a desired surface to which it is applied. Embodiments of the compounds may be exemplified by the formula:
Q-[(OA) n -OR] m | 1. A liquid thickener composition comprising:
1) 20%-80% of the polyalkoxylated polyols polyester of the formula;
Q-[(OA)n-OR]m Formula-2
Q is a radical of organic polyol compounds, having 6 to 50 carbon atoms, and is saturated or unsaturated, straight, branched or cyclic chain structure, and independently substit... | Compounds contained herein relate to polyalkoxylated polyol polyester having a viscosity that allows a product to be poured, yet retained on a desired surface to which it is applied. Embodiments of the compounds may be exemplified by the formula:
Q-[(OA) n -OR] m1. A liquid thickener composition comprising:
1) ... | 1,600 |
1,294 | 1,294 | 15,099,909 | 1,649 | The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc. | 1. A method of treating degenerative disc disease (DDD), comprising:
obtaining an MRI of a proximal tissue in a patient having DDD; assigning a quantified value for the selected tissue based upon the MRI; and comparing the quantified value against a pre-determined value, wherein if the quantified value is greater than ... | The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.1. A method of treating degenerative disc disease (DDD), comprising:
obtaining an MRI of a proximal tissue in a patient having DDD; assigning a quantified value for the selected tissue based upon the MR... | 1,600 |
1,295 | 1,295 | 15,452,067 | 1,615 | An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of be... | 1. An apparatus, comprising:
a medical tablet including an integrated circuit (IC) chip member equipped with an IC therein, said medical tablet having a first surface and a second surface opposite the first surface, wherein an engraved stamp or cleavage line is formed in said first surface, an engraved stamp or cleavag... | An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of be... | 1,600 |
1,296 | 1,296 | 15,189,177 | 1,617 | A composition and method of treating patients diagnosed with NAFLD is disclosed. The composition contains n-3 polyunsaturated fatty acids (PUFAs) for treatment of NAFLD patients, wherein the amount of PCB 153 in the composition has been minimized. The composition is administered to a patient in a sufficient amount and ... | 1. A method of treating a patient diagnosed with non-alcoholic fatty liver disease (NAFLD) comprising administering an n-3 polyunsaturated fatty acids (n-3 PUFAs) composition to the patient in a sufficient amount to increase a level of n-3 PUFAs or to correct a deficiency of n-3 PUFAs in the blood of the patient, where... | A composition and method of treating patients diagnosed with NAFLD is disclosed. The composition contains n-3 polyunsaturated fatty acids (PUFAs) for treatment of NAFLD patients, wherein the amount of PCB 153 in the composition has been minimized. The composition is administered to a patient in a sufficient amount and ... | 1,600 |
1,297 | 1,297 | 11,004,617 | 1,627 | The present invention is a cosmetic or dermatological preparation comprising 0.01% by weight to 5% by weight of at least one red light-filtering dye and 0.0001% by weight to 10% by weight of at least one anti-inflammatory active ingredient. The preparation can be used for the prophylaxis and treatment of sun-irritated ... | 1. A cosmetic or dermatological preparation, comprising:
0.01% by weight to 5% by weight of at least one red light-filtering dye; and 0.0001% by weight to 10% by weight of at least one anti-inflammatory active ingredient. 2. The preparation according to claim 1, wherein the anti-inflammatory active ingredient include... | The present invention is a cosmetic or dermatological preparation comprising 0.01% by weight to 5% by weight of at least one red light-filtering dye and 0.0001% by weight to 10% by weight of at least one anti-inflammatory active ingredient. The preparation can be used for the prophylaxis and treatment of sun-irritated ... | 1,600 |
1,298 | 1,298 | 13,545,473 | 1,653 | A temperature sensor for monitoring an organ or tissue is configured to measure a temperature inside of a container configured to contain the organ or tissue. The temperature sensor is disposed exterior to the organ container and the temperature sensor is a non-contact temperature sensor. The temperature sensor may be ... | 1. An apparatus for perfusing, transporting, and/or storing an organ or tissue, comprising:
a coolant container configured to contain coolant and define a compartment to hold another container; and a non-contact temperature sensor configured to measure a temperature of a space inside of the compartment, the non-contact... | A temperature sensor for monitoring an organ or tissue is configured to measure a temperature inside of a container configured to contain the organ or tissue. The temperature sensor is disposed exterior to the organ container and the temperature sensor is a non-contact temperature sensor. The temperature sensor may be ... | 1,600 |
1,299 | 1,299 | 15,463,752 | 1,644 | The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to... | 1. A chimeric immunoglobulin heavy chain comprising a human variable domain and a chimeric constant region comprising a human CH1 domain, a human upper hinge region, a non-human CH2 domain, and a non-human CH3 domain. 2. The chimeric immunoglobulin heavy chain according to claim 1, wherein the CH1 domain isotype is IgM... | The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.